Ask AI
ProCE Banner Activity

From Testing to Treatment: Expert Perspectives on HER2-Targeted ADCs in Advanced Bladder Cancer

Clinical Thought

In this commentary, experts highlight the rapidly evolving treatment landscape of advanced urothelial carcinoma, emphasizing the importance of early HER2 testing, appropriate use of HER2-targeted antibody–drug conjugates, and proactive toxicity management to optimize patient outcomes.

Released: April 09, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity has been designed to meet the educational needs of oncologists, urologists, pathologists, and other healthcare professionals who care for patients with bladder cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Perform molecular testing and interpretation concordant with expert recommendations to identify patients with advanced bladder cancer who are most likely to benefit from established or emerging HER2-targeted ADCs

  • Evaluate the potential clinical implications of emerging data for novel HER2-targeted ADCs on management of HER2-positive advanced bladder cancer

  • Plan individualized treatment sequences leveraging HER2-targeted ADCs for eligible patients with advanced bladder cancer based on the latest evidence, guidelines, and patient/disease factors

  • Develop strategies to anticipate, monitor, and manage AEs associated with HER2-targeted ADCs in patients with advanced bladder cancer

Disclosure

Primary Author

Shilpa Gupta, MD: consultant/advisor/speaker: Astellas, Bristol Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer.

Vadim S. Koshkin, MD: consultant/advisor/speaker: Astellas, Bicycle, Bristol Myers Squibb, Janssen, Loxo Oncology, Merck, Natera, Pfizer, Roche/Genentech; researcher: Astellas, Gilead, Lilly, Pfizer, Taiho, Tyra Oncology.

Daniel P. Petrylak, MD: consultant/advisor/speaker: Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Bicycle, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis, Gilead, Incyte, Infinity, Ipsen, Janssen, Merck, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Sanofi-Aventis, Seattle Genetics, Urogen; researcher: Ada Cap, Agensys, Arvians, Astellas, AstraZeneca, Bayer, BioXcel, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Eisai, Endocyte, Ferring, Genentech, Gilead, Innocrin, Lilly, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi-Aventis, Seattle Genetics.